The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

The Globe and Mail has
updated our Stock Quote Pages
You are about to experience the newly designed Stock Quote Pages format. With the new layout, you'll enjoy a more in-depth look at the companies you're following and pages that are easier to navigate. This Editors' blog post explains why we've made these changes.

 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $57.54

Today's change-0.09 -0.16%
Updated May 22 4:03 PM EDT. Delayed by at least 15 minutes.
 

Novo Nordisk A/S

NYSE: NVO
Last

(U.S.) $57.54

Today's change-0.09 -0.16%
Updated May 22 4:03 PM EDT. Delayed by at least 15 minutes.

Novo Nordisk A/S down (U.S.)$0.09

Novo Nordisk A/S closed lower Friday, dropping (U.S.)$0.09 or 0.16% to (U.S.)$57.54. Over the last five days, shares have gained 1.39% and 35.96% year to date. Shares have outperformed the S&P 500 by 21.72% during the last year.

Key company metrics

  • Open(U.S.) $57.19
  • Previous close(U.S.) $57.63
  • High(U.S.) $57.64
  • Low(U.S.) $57.04
  • Bid / Ask-- / --
  • YTD % change+35.96%
  • Volume1,031,980
  • Average volume (10-day)780,754
  • Average volume (1-month)1,160,431
  • Average volume (3-month)1,565,256
  • 52-week range(U.S.) $41.72 to (U.S.) $57.70
  • Beta0.91
  • Trailing P/E34.16×
  • P/E 1 year forward31.89×
  • Forward PEG2.06×
  • Indicated annual dividend(U.S.) $0.76
  • Dividend yield1.32%
  • Trailing EPS(U.S.) $1.68
Updated May 22 4:03 PM EDT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
+31.92%

Based on its net profit margin of 31.92%, Novo Nordisk A/S is among the more effective companies in its industry at turning revenues into bottom line profit.
Company Books

S&P TSX0.03%Sector:Industry:
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2015Q4/2014Q3/2014Q2/2014
Fiscal Quarter Endvalues in $ millions unless otherwise notedMar 31, 201503/31/2015Dec 31, 201412/31/2014Sep 30, 201409/30/2014Jun 30, 201406/30/2014
Revenue25,20024,58522,24921,629
Total other revenue--------
Total revenue25,20024,58522,24921,629
Gross profit21,32620,58618,82317,958
Total cost of revenue3,8743,9993,4263,671
Total operating expense11,34315,42813,68012,896
Selling / general / administrative7,0017,7466,7696,354
Research & development3,2503,8653,6543,075
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)-2,376------
Other operating expenses, total-406-182-169-204
Operating income13,8579,1578,5698,733
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax12,4858,3528,4548,989
Income after tax9,8766,5296,5006,994
Income tax, total2,6091,8231,9541,995
Net income9,8766,5296,5006,994
Total adjustments to net income--------
Net income before extra. items9,8766,5296,5006,994
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items9,8766,5296,5006,994
Inc. avail. to common incl. extra. items9,8766,5296,5006,994
Diluted net income9,8766,5296,5006,994
Dilution adjustment00--0
Diluted weighted average shares2,6042,6302,6222,637
Diluted EPS excluding extraordinary itemsvalue per share3.792.482.482.65
Dividends per sharevalue per share0.005.110.000.00
Diluted normalized EPSvalue per share3.072.482.482.65